Informed Prostate Cancer Patient Support

DNA repair gene polymorphisms, tumor control, and treatment toxicity in prostate cancer patients treated with permanent implant prostate brachytherapy - Carignan - - The Prostate - Wiley Online Library : Background Radiotherapy and brachytherapy are common treatments for localized prostate cancer (PCa). However, very few studies evaluated the association of variations in DNA damage response genes an...

New diagnostic tools aim to catch aggressive prostate cancer early : Two newly published studies are presenting novel diagnostic techniques to help catch the most aggressive forms of prostate cancer at an early stage. A University of East Anglia study presents an innovative way to measure gene expression in tumor samples and predict disease severity, while an…

Improved Imaging for Prostate Cancer With PSMA PET-CT : A novel imaging technique was more accurate than conventional CT with bone scanning at detecting pelvic and distant metastases in high-risk prostate cancer.

'MultiD': Taking the Bias Out of Prostate Cancer Tx | MedPage Today : No, it's not a vitamin, it's a new model of care planning

Older Patients With Cancer Especially Vulnerable to Coronavirus - MedicineNet Health News : For oncologists and other clinicians caring for patients with cancer, the COVID-19 pandemic represents a dynamic clinical challenge that is changing daily and that can feel overwhelming at times, say experts.

Study: Prostate Cancer Leaves Detectable ‘Fingerprint’ in Blood | Cooking with Kathy Man : A test that can detect the genetic “fingerprint” of prostate cancer in blood could improve diagnosis, monitoring and treatment of the disease, researchers say. The test checks for prost…

Plasma cell-free DNA-based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancer | Prostate Cancer and Prostatic Diseases : The combination of abiraterone acetate and prednisone (AA/P) is used to treat metastatic prostate cancer, but molecular predictors of treatment response are not well elucidated. We evaluated plasma circulating tumor DNA- (ctDNA-) based copy number alterations (CNAs) to determine treatment-related predictive and prognostic biomarkers for metastatic castration-resistant prostate cancer (mCRPC). Serial plasma specimens were prospectively collected from 88 chemotherapy-naive mCRPC patients before and after 12 weeks of AA/P treatment. Sequencing-based CNA analyses were performed on 174 specimens. We evaluated CNA-associated 12-week responses for primary resistance, time to treatment change (TTTC) for secondary resistance, and overall survival for prognosis (P < 0.05). Associations with prim

Exercise Helps Men During Hormone Treatment for Prostate Cancer: Study : Exercise benefits prostate cancer patients who undergo hormone-reducing therapy, a small study suggests.

Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. : The optimal treatment for men with high-risk localized or locally advanced prostate cancer (PCa) remains unknown.To perform a systematic review of the existing literature on the effectiveness of the different primary treatment modalities for high-risk localized and locally advanced PCa.

The role of fatal family history and mode of inheritance in prostate cancer for long-term outcomes following radical prostatectomy - Docwire News : Purpose: To determine whether fatal family history (FFH) or mode of inheritance in prostate cancer (PCa) has an impact on long-term outcomes following

Dr. Fendler on the Utility of 68Ga-PSMA-11 PET in Prostate Cancer : Wolfgang Fendler, MD, discusses the utility of 68Ga-PSMA-11 PET in prostate cancer.

Exercise beneficial during hormone treatment for prostate cancer - UPI.com : Exercise benefits prostate cancer patients who undergo hormone-reducing therapy, a small study suggests.

Knockdown of lncRNA TUG1 Enhances Radiosensitivity of Prostate Cancer | OTT : Knockdown of lncRNA TUG1 Enhances Radiosensitivity of Prostate Cancer via the TUG1/miR-139-5p/SMC1A Axis

Knockdown of lncRNA TUG1 Enhances Radiosensitivity of Prostate Cancer | OTT : Knockdown of lncRNA TUG1 Enhances Radiosensitivity of Prostate Cancer via the TUG1/miR-139-5p/SMC1A Axis

Health Beat: Predicting prostate cancer | Health Beat | wfmz.com : Prostate cancer is the second-most commonly diagnosed cancer in men worldwide after lung cancer, but 3.1 million men are also living with it, and there's not a lot that men

Charged particles kill cancer by clogging up its waste disposal unit : There are many tools cancer relies on to survive and thrive, and therefore many possibilities when it comes to thwarting its advances. One such avenue centers on cellular garbage disposal units known as lysosomes, which are particularly vulnerable in cancer cells as opposed to healthy ones. And…

Antidepressant shows promise in treating recurrent prostate cancer : A USC pilot study — the first clinical trial of this drug in cancer patients — reported lower prostate-specific antigen levels in more than half of the participants.

'MultiD': Taking the Bias Out of Prostate Cancer Tx | MedPage Today : No, it's not a vitamin, it's a new model of care planning

News digest – microbial 'signatures', aspirin and liver cancer, vaping and coronavirus - Cancer Research UK - Science blog : Scientists have discovered it's possible to identify some cancers by searching for microbial DNA 'signatures' in the blood.

Prostate Cancer Leaves Detectable 'Fingerprint' in Blood: Study : A test that can detect the genetic fingerprint of prostate cancer in blood could improve diagnosis, monitoring and treatment of the disease, researchers say.

A pilot window-of-opportunity study of preoperative fluvastatin in localized prostate cancer | Prostate Cancer and Prostatic Diseases : Statins inhibit HMG-CoA reductase, the rate-limiting enzyme of the mevalonate pathway. Epidemiological and pre-clinical evidence support an association between statin use and delayed prostate cancer (PCa) progression. Here, we evaluated the effects of neoadjuvant fluvastatin treatment on markers of cell proliferation and apoptosis in men with localized PCa. Thirty-three men were treated daily with 80 mg fluvastatin for 4–12 weeks in a single-arm window-of-opportunity study between diagnosis of localized PCa and radical prostatectomy (RP) (ClinicalTrials.gov: NCT01992042). Percent Ki67 and cleaved Caspase-3 (CC3)-positive cells in tumor tissues were evaluated in 23 patients by immunohistochemistry before and after treatment. Serum and intraprostatic fluvastatin concentrations were quantified by liquid chromatography-mass spectrometry. Baseline character

Combined MRI and Ultrasound Prostate Biopsy: 'Paradigm Shift' : Combining both techniques reveals more clinically significant cancers, and represents a 'paradigm shift' in diagnosis, but expert hands and eyes are needed.

Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis | Prostate Cancer and Prostatic Diseases : This systematic review and meta-analysis aimed to assess the prognostic value of sequential of abiraterone (ABI) and enzalutamide (ENZ) therapy in patients with castration-resistant prostate cancer (CRPC). PUBMED, Web of Science, Cochrane Library, and Scopus databases were searched for articles published prior to December 2019 according to the Preferred Reporting Items for Systematic Review and Meta-analysis statement. Studies were deemed eligible if they compared overall survival (OS), combined progression-free survival (PFS), combined prostate specific antigen (PSA)-PFS, and PSA response rates in CRPC patients receiving sequential ABI/ENZ or vice versa. PSA response to both the first and second agents was defined as a >50% decrease in PSA achieved with each of these agents. Formal meta-analyses were performed f

Researchers Announce Progress in Developing an Accurate, Noninvasive Urine Test For Prostate Cancer | Cooking with Kathy Man : Researchers at the Johns Hopkins Kimmel Cancer Center have made significant progress toward development of a simple, noninvasive liquid biopsy test that detects prostate cancer from RNA and other s…

Decades-old antidepressant may fend off prostate cancer's return: MAO inhibitor disrupts tumor growth pathway -- ScienceDaily : An antidepressant from the '50s, repurposed to fight prostate cancer, lowered PSA levels in men with recurrent disease, pilot study shows.

Promising progress on blood and urine tests for prostate cancer : Two new studies are offering promising progress in the development of novel diagnostic tests to detect and monitor prostate cancer. The research presents a urine test that can detect the disease in its early stages and a blood test that may catch the cancer as it begins to metastasize.

Integrated RNA and metabolite profiling of urine liquid biopsies for prostate cancer biomarker discovery | Scientific Reports : Sensitive and specific diagnostic and prognostic biomarkers for prostate cancer (PCa) are urgently needed. Urine samples are a non-invasive means to obtain abundant and readily accessible “liquid biopsies”. Herein we used urine liquid biopsies to identify and characterize a novel group of urine-enriched RNAs and metabolites in patients with PCa and normal individuals with or without benign prostatic disease. Differentially expressed RNAs were identified in urine samples by deep sequencing and metabolites in urine were measured by mass spectrometry. mRNA and metabolite profiles were distinct in patients with benign and malignant disease. Integrated analysis of urinary gene expression and metabolite signatures unveiled an aberrant glutamate metabolism and tricarboxylic acid (TCA) cycle node in prostate cancer-derived cells. Functional validation supported a role

Progress in developing an accurate, noninvasive urine test for prostate cancer -- ScienceDaily : Researchers have made significant progress toward development of a simple, noninvasive liquid biopsy test that detects prostate cancer from RNA and other specific metabolic chemicals in the urine.

The Power of Hand-Washing to Prevent Coronavirus : The single most important way to help us stay safe from COVID-19 is this one: Wash your hands. But people don't do it right, experts say.

Lose Weight, Lower Prostate Cancer Risk - WebMD : Having a BMI (body mass index -- an estimate of body fat based on height and weight) above the range that's considered healthy (21-25) during middle to late adulthood was associated with the highest risk for advanced prostate cancer.

Assessing Patient Perceptions of the Incorporation of Diet, Exercise and Weight Management into Cancer Care Survey : Take this survey powered by surveymonkey.com. Create your own surveys for free.

Combined Biopsy Tops MRI, TRUS for Prostate Cancer | MedPage Today : Fewer clinically insignificant diagnoses, less upgrading after surgery

Dual Method May Boost Accuracy of Prostate Cancer Diagnosis : Adding MRI to a standard tissue biopsy appears to enhance the accuracy of a prostate cancer diagnosis, new research finds.

Engineered bone marrow cells slow growth of prostate and pancreatic cancer cells | EurekAlert! Science News : In experiments with mice, researchers at the Johns Hopkins Kimmel Cancer Center say they have slowed the growth of transplanted human prostate and pancreatic cancer cells by introducing bone marrow cells with a specific gene deletion to induce a novel immune response.

Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations | Prostate Cancer and Prostatic Diseases : The androgen receptor (AR) is a key prostate cancer drug target. Suppression of AR signaling mediated by the full-length AR (AR-FL) is the therapeutic goal of all existing AR-directed therapies. AR-targeting agents impart therapeutic benefit, but lead to AR aberrations that underlie disease progression and therapeutic resistance. Among the AR aberrations specific to castration-resistant prostate cancer (CRPC), AR variants (AR-Vs) have emerged as important indicators of disease progression and therapeutic resistance. We conducted a systemic review of the literature focusing on recent laboratory studies on AR-Vs following our last review article published in 2016. Topics ranged from measurement and detection, molecular origin, regulation, genomic function, and preclinical therapeutic targeting of AR-Vs. We provide expert opinions and perspectives on these

HSD3B1 May Be Associated with Earlier Castration Resistance, Shorter OS in Prostate Cancer | Cancer Network : HSD3B1 may help identify more men who are likely to benefit from escalated androgen receptor axis inhibition beyond gonadal testosterone suppression according to the researchers.

Boundary-Weighted Domain Adaptive Neural Network for Prostate MR Image Segmentation - IEEE Journals & Magazine

Docetaxel‐resistant prostate cancer cells become sensitive to gemcitabine due to the upregulation of ABCB1 - Seo - - The Prostate - Wiley Online Library : Background Docetaxel is the preferred chemotherapeutic agent for hormone‐refractory prostate cancer (PC) patients. However, patients eventually develop docetaxel resistance, and no effective treatme...

MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis | NEJM : Original Article from The New England Journal of Medicine — MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis

Phase II Trial Results Show Promise for Phenelzine in Prostate Cancer | Cancer Network : Phase II trial results found that phenelzine, a monoamine oxidase inhibitor typically used as an antidepressant, showed promise for patients with biochemical recurrent castrate-sensitive prostate cancer.

Testing with combined biopsy method improves prostate cancer diagnosis in NIH study | National Institutes of Health (NIH) : Improved diagnosis could reduce the risk of both overtreatment and undertreatment of the disease

Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines - Shore - - The Prostate - Wiley Online Library : Background For specific clinical indications, androgen deprivation therapy (ADT) will induce disease prostate cancer (PC) regression, relieve symptoms and prolong survival; however, ADT has a well‐d...

PSA Testing and Prostate Cancer Incidence Following the 2012 Update to the U.S. Preventive Services Task Force Prostate Cancer Screening Recommendation: Implications for Racial/Ethnic Disparities | Cancer Epidemiology, Biomarkers & Prevention : The 2012 U.S. Preventive Services Task Force (USPSTF) recommendation against prostate specific antigen (PSA) testing led to a decrease in prostate cancer screening, but its impact on prostate cancer racial/ethnic disparities remains unclear. Methods: The proportion of men ages 40–74 years who received a routine PSA test in the past year was estimated over time in the Behavioral Risk Factor Surveillance System (BRFSS; 2012–2018) and the National Health Interview Survey (NHIS; 2005–2018). Screening trends by race/ethnicity were evaluated using logistic regression models to estimate odds ratios (ORs) of screening adjusting for socioeconomic and healthcare-related factors. Prostate cancer incidence rates and rate ratios (IRRs) by race/ethnicity

Before Prostate Surgery, Consider ‘Active Surveillance’ - The New York Times : Not to be confused with “watchful waiting,” active surveillance is not a do-nothing approach.

Debating the Value of PSA Prostate Screening - The New York Times : Personal health Debating the Value of PSA Prostate Screening In many men identified as having prostate cancer following PSA screening, the disease is neither aggressive nor likely to kill them before something else does. Credit...Gracia Lam Jane E. Brody By Jane E. Brody Published Feb. 24, 2020 Updated Feb. 25, 2020 We’ve long been schooled on the lifesaving value of early detection of a potentially deadly cancer. So when a simple blood test was introduced in 1994 that could detect the possible presence of prostate cancer, the second leading cause of cancer deaths among American men, it’s not hard to understand why it quickly became hugely popular. Suddenly, in the decades following approval of the test known as the PSA, for prostate-specific antigen, the number of men receiving a diagnosis of prostate cancer skyrocketed, along with the number undergoing biopsies of this walnut-size gland between

https://play.google.com/music/m/I7ydyv3ao7lkmrgapv6vfnodpuu?t=PROSTATE_PROS PROSTATE PROS Mark Scholz, MD Prostate cancer is complex. Patients often struggle to find accurate, stage-specific information. Listen as prostate specialist and author, Mark Scholz, MD guides you through the 15 stages of prostate cancer, recent updates, and all possible treatment options. Avoid prostate cancer pitfalls and take control of your diagnosis with the PROSTATE PROS podcast. 11 episodes

Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer | Prostate Cancer and Prostatic Diseases : Monoamine oxidase A (MAOA) influences prostate cancer growth and metastasis in pre-clinical models. We examined effects of phenelzine (a monoamine oxidase inhibitor) in patients with biochemical recurrent castrate-sensitive prostate cancer. An open-label single arm clinical trial enrolled subjects with biochemical recurrent prostate cancer defined by PSA ≥ 0.4 ng/ml (post prostatectomy) or PSA ≥ 2 ng/ml above nadir (post-radiation therapy); no evidence of metastasis on imaging; and normal androgen levels. Subjects received phenelzine 30 mg orally twice daily. Mood symptoms were assessed with the hospital anxiety depression score (HADS) questionnaire. The primary endpoint was the proportion of patients who achieved a PSA decline of ≥50% from baseline. Characteristics of the 20 eligible patients enrolled included: mean ± SD age 66.9 ± 4.8 years and P

Spironolactone use is associated with lower prostate cancer risk: a population-wide case-control study | Prostate Cancer and Prostatic Diseases : Spironolactone, a cheap effective diuretic used to manage hypertension and heart failure, also has anti-androgenic effects through its non-selective binding to steroid receptors, and hence may affect prostate cancer (PCa) risk. This study investigated the association between spironolactone use and PCa risk. For comparison, we also examined associations with thiazide diuretics which do not have anti-androgenic properties. A matched case-control study was undertaken using population-wide data from the Prostate Cancer Data Base Sweden (PCBaSe). All PCa cases diagnosed from 2014 to 2016 were matched by birth year and county with PCa-free controls selected from the general population (1:5). Multivariable conditional logistic regression was used to examine associations between spironolactone use (dose and duration) and PCa risk, and similarly for t

Observer Agreement and Accuracy of 18F-Sodium Fluoride PET/CT in the Diagnosis of Bone Metastases in Prostate Cancer

18F-Choline PET/mpMRI for Detection of Clinically Significant Prostate Cancer: Part 1. Improved Risk Stratification for MRI-Guided Transrectal Prostate Biopsies

Theranostics: Leveraging Molecular Imaging and Therapy to Impact Patient Management and Secure the Future of Nuclear Medicine

Total-Body 68Ga-PSMA-11 PET/CT for Bone Metastasis Detection in Prostate Cancer Patients: Potential Impact on Bone Scan Guidelines

Prostatepedia Weekly 2.29.2020

Survey on imaging in the management of prostate cancer | THE "NEW" PROSTATE CANCER INFOLINK : Members of the Coalition for Biomedical Imaging and Bioengineering Research (CIBR) are interested in patient perspectives  and experiences in relation to imaging in the diagnosis, work-up, and mana…

Medical Imaging - Patient Perception for Individuals Undergoing Prostate Care Survey : Take this survey powered by surveymonkey.com. Create your own surveys for free.